Skip to main content
. 2016 Apr 6;11(4):e0152384. doi: 10.1371/journal.pone.0152384

Fig 7. Induction of CD4+ T cell lines that are reactive to cancer antigens by CD14-ML-DC obtained from HNC patients.

Fig 7

CD4+ T cells isolated from PBMCs of HNC patients were stimulated with CD14-ML-DC that were pulsed with a mixture of 6 kinds of peptides (CDCA139-64, CDCA155-78, KIF20A60-84, KIF20A809-833, LY6K119-142 and LY6K172-191). After more than three rounds of stimulation, the number of CD4+ T cells that reacted to each peptide was analyzed by ELISPOT assay. CD14-ML-DC were used as stimulators in the assay, because only a few amount of blood samples could be obtained from cancer patients. The results for cancer patient 1 (A) and cancer patient 2 (B) are shown.